Semavic (semaglutide) [Ozempic]

Instructions for Semavic (semaglutide) [Ozempic]

Semaglutide, the active ingredient of Semavik, is a glucagon-like peptide-1 (GLP-1R) receptor agonist that is chemically synthesized. It is intended for the treatment of type 2 diabetes mellitus and is effective at least on 6 of the 8 pathogenesis links of this disease. Semaglutide contributes to the improvement of the course and outcome of diabetes, as well as positively affects the quality of life of patients.

Mechanism of action Ozempic:

Semaglutide exhibits its pharmacological effects by lowering blood glucose and weight. It also has a beneficial effect on plasma lipid profile by lowering systolic blood pressure and insulin resistance.

Effects on weight Semavic:

Semaglutide contributes to a decrease in total body weight and body fat volume by reducing energy consumption. Mechanisms of action include

General reduction of appetite;

Strengthen saturation signals and reduce hunger signals;

Improving the control of food consumption and reducing craving for it;
Reducing preference for high-fat foods

Method of application Semavic:

Given a semaglutide half-life of about one week, semaglutide can be injected subcutaneously once a week to be convenient for patients.
In general, semaglutide is effective for controlling blood glucose levels, controlling body weight, and improving the general health of people with type 2 diabetes.

Pharmacodynamics of semaglutide

All pharmacodynamic studies of semaglutide were conducted after 12 weeks of therapy, including the period of dose increase, while maintaining an equilibrium concentration of 1 mg once a week.

Fasting and postprandial glycemia Ozempic
Semaglutide demonstrates a significant decrease in both fasting and postprandial glucose concentrations. Compared with placebo, 1-mg semaglutide therapy in patients with type 2 diabetes mellitus (DM2) resulted in the following:
Fasting glucose concentration: 1.6 mmol/L (or 22%) decrease.

Glucose concentration 2 hours after meals: 4.1 mmol/L (or 37%) decrease.
Mean daily glucose concentration: 1.7 mmol/L (or 22%) decrease.
Postprandial peaks in glucose concentration: Decrease in the range of 0.6 to 1.1 mmol/L after 3 meals.
It should be noted that semaglutide reduced fasting glucose concentrations after the first dose. These findings suggest the efficacy of semaglutide in controlling glucose levels in patients with DM2.